When it comes to trevi Therapeutics To Participate In upcoming march conferences, trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company, is set to engage in key investor conferences this March, spotlighting its investigational therapy, Haduvio™. This oral nalbuphine extended-release treatment aims to address chronic cough in patients suffering from idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, as well as refractory chronic cough (RCC).
Understanding Trevi Therapeutics To Participate In Upcoming March Conferences
Trevi Therapeutics' senior management will participate in two significant events: the Leerink Partners 2026 Global Healthcare Conference and the Access USA Rare Disease Summit 2026. The Leerink Partners conference will take place from March 8 to 11 in Miami, Florida, where Jennifer Good, Trevi's President and CEO, and James Cassella, Ph.D., the Chief Development Officer, are scheduled for a fireside chat on March 11 at 8:40 a.m. ET. Investors can register to watch this session live via webcast. Learn more on Investopedia.
Following this, Trevi's Chief Commercial Officer, Farrell Simon, Pharm.D., will represent the company at the Access USA Rare Disease Summit in Philadelphia from March 17 to 19. Simon will participate in a panel discussion titled "Architecting Success - Building a Foundation for Rare Disease Launch Excellence" on March 18 from 9:00 to 9:45 a.m. ET. This summit provides a platform for discussing strategies in launching therapies for rare diseases, aligning perfectly with Trevi's mission.
Haduvio™: A Potential Game Changer
Haduvio™ is at the forefront of Trevi Therapeutics' efforts to tackle chronic cough conditions that currently lack FDA-approved treatments. The therapy has shown statistically significant reductions in cough frequency during clinical trials for both patients with chronic cough related to IPF and those with RCC. By acting as a kappa agonist and mu antagonist (KAMA), Haduvio targets opioid receptors critical in regulating chronic cough, thus offering hope to patients with few existing options.
Chronic cough is a debilitating symptom for many, especially those with IPF and non-IPF ILD. Approximately 150,000 individuals in the U.S. are diagnosed with IPF, and an alarming two-thirds of these patients experience uncontrolled chronic cough. Similarly, with around 228,000 patients suffering from non-IPF ILD, 50 to 60 percent also battle chronic cough. The implications of such persistent symptoms are profound, contributing to increased morbidity, hospitalizations, and a significant decline in patients' quality of life.
Addressing Unmet Medical Needs
The need for effective treatments for chronic cough is underscored by the staggering numbers of patients affected. Chronic cough, defined as a cough lasting more than eight weeks despite treatment for underlying conditions, affects an estimated 2 to 3 million people in the U.S. This condition is often tied to cough reflex hypersensitivity, which can complicate the management of related illnesses like asthma or gastroesophageal reflux disease.
Trevi Therapeutics is focused on filling the void in this therapeutic landscape. The company's commitment to developing Haduvio is driven by the significant unmet needs observed in these patient populations. With no FDA-approved therapies currently available, the potential approval and market introduction of Haduvio could represent a significant advancement for patients suffering from chronic cough.
Looking Ahead
As Trevi Therapeutics prepares for its upcoming conferences, the biopharmaceutical company is poised to showcase its innovative approach to addressing chronic cough. The dialogues at these events will not only highlight Haduvio's potential but also enhance understanding of the challenges faced by patients living with these conditions. With the support of its management team and engagement with the healthcare community, Trevi aims to accelerate the journey toward bringing meaningful therapies to market.
In a landscape where chronic cough remains inadequately addressed, Trevi Therapeutics stands at the forefront of a promising solution. The upcoming March conferences will serve as a critical platform for sharing insights, fostering partnerships, and ultimately driving forward the mission to improve patient outcomes.
Originally reported by Globenewswire_fr. View original.